NOVALIQ-GMBH
24.4.2018 17:55:11 CEST | Business Wire | Press release
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3).
The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma.
Scientific posters supported by Novaliq will include:
- “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schmidl D., Werkmeister R., Adzhemian N., Kosobokovs S., Krösser S., Schmetterer L. Poster presentation on Sunday, April 29, 3:15-5:00 PM; Poster Board: B0119
- “Ocular and Systemic Distribution of 14 C- Perfluorohexyloctane following Topical Ocular Administration to Rabbits.” Authors: Krösser S., Spencer E., Grillenberger R., Struble C., Eickhoff K. Poster presentation on Tuesday, May 1, 8:15-10:00 AM; Poster Board: A0383
- “Evaluating the lubricating effect of semifluorinated alkanes on the ocular surface.” Authors: Agarwal P., Khun D., Krösser S., Eickhoff K., Wells F. S., Willmott G. R., Craig J. P., Rupenthal I. D. Poster presentation on Tuesday, May 1, 11:15-13:00 AM; Poster Board: C0076
- “The pharmacodynamic effect of LatanoSol eye drops on IOP of normotensive dogs.” Authors: Eickhoff K., Prusakiewicz J., Uhlmann L., Struble C., Löscher F., Krösser S. Poster presentation on Tuesday, May 1, 8:15-10:00 AM; Poster Board: B0037
“We are proud to share and discuss the scientific data on our innovative and water-free platform technology with researchers, clinicians, and industry,” said Sonja Krösser, PhD, VP Preclinical and Clinical Development, Novaliq. “Our dedication to science is the basis for advancing our unique pipeline and developing innovative products that help physicians better serve their patients.”
The Novaliq team will be available at ARVO 2018 in Honolulu, HI to discuss the research and to answer questions. To arrange a meeting, please send an email to event@novaliq.com with day and time preference.
About Novaliq – Founded in 2007, Novaliq GmbH is a Heidelberg-based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq’s proprietary EyeSol® technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases, including dry eye through preservative-free and multi-dose formulations. Novaliq has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. The company’s most advanced products are NovaTears® with CE-approval marketed under the brand name EvoTears® in Europe, and NovaTears®+Omega-3, which was just recently CE-approved in Europe. CyclASol®, a second-generation prescription drug, is currently in pivotal phase of clinical development. More on www.novaliq.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180424006177/en/
Contact:
For US:
Michele Gray, + 1 (917) 449-9250
Principal, Gray
Communications, LLC.
michele_gray@me.com
or
For
EU/Asia:
Heidrun Kirsch, + 49 6221 50259 243
VP Marketing
hkirsch@novaliq.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqara Showcases Scaling Professional-Grade Infrastructure and Unified Management at Light + Building 20268.3.2026 09:00:00 CET | Press release
From system-level software to end-to-end solutions, Aqara demonstrates how intelligent spaces are designed, operated, and scaled. Aqara, a global leader and pioneer in IoT, today unveiled its cutting-edge innovations in intelligent space technology at Light + Building 2026 (Hall 9.0, Booth A50). Aqara’s demonstration offers a glimpse into a comprehensive system that offers intelligent lighting control, energy saving, and space security experience for professional usage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260308903989/en/ Aqara Showcases Scaling Professional-Grade Infrastructure and Unified Management at Light + Building 2026 System-level Intelligent Control Aqara introduces a centralized system solution designed to streamline the management of building deployments at any scale. Moving beyond individual device control, Aqara offers a unified solution that provides architects, facility managers, and developers with
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom